Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Noetic Fund invests in a wide array of sectors related to mental health, including biotech, healthcare, digital health, artificial intelligence, fintech, consumer products, food-agtech, the creator economy, edtech, and longevity. The firm is particularly interested in novel drug therapeutics, psychedelic-assisted therapies, digital health solutions, medical devices, and wearables. Their investment strategy emphasizes treatments that address the root causes of illness, focusing on early intervention and prevention.
The firm seeks to back companies that are developing innovative solutions to optimize human experience and improve mental health outcomes. This includes a commitment to evidence-backed solutions that demonstrate efficacy in addressing mental health challenges. Noetic Fund's global outlook allows it to identify and support promising startups across various geographic regions, with a strong presence in North America.
By investing in early-stage technologies, Noetic Fund aims to contribute to the advancement of sustainable therapies and products that enhance mental, emotional, and physiological health. The firm values founders who are passionate about making a difference in the mental health space and who are committed to developing solutions that can have a meaningful impact on individuals and communities.
Noetic Fund's portfolio consists of 26 companies, showcasing a diverse range of innovations in the mental health sector. Notable investments include COMPASS Pathways, MindMed, and Cybin, all of which have achieved significant milestones, including IPOs. COMPASS Pathways is focused on accelerating access to mental health innovations, while MindMed and Cybin are pioneering advancements in psychedelic-assisted therapies.
Other key portfolio companies include Apollo Neuroscience, which develops solutions to enhance resilience to stress, and Beckley Psytech, which is dedicated to exploring psychedelic compounds for neurological disorders. Delix Therapeutics is also part of the portfolio, contributing to the development of novel treatments for mental health conditions.
The firm has successfully supported its portfolio companies through strategic guidance and access to a network of industry professionals, emphasizing the importance of evidence-backed solutions in the mental health space. With a multi-modal approach that includes drug therapeutics, digital health, and medical devices, Noetic Fund is well-positioned to foster innovation and drive advancements in mental health treatments.
Michael Franks - Co-Founder, brings extensive experience in mental health technologies and investment strategies.
Sa'ad Shah - Co-Founder, focuses on identifying innovative solutions in the mental health sector.
Naseem Saloojee - Co-Founder, has a strong background in venture capital and mental health initiatives.
To pitch Noetic Fund, founders should visit their website at noeticfund.com. The firm welcomes pitches that highlight innovative mental health solutions, particularly those that are evidence-backed. They prefer direct applications through their website rather than relying solely on warm introductions.
Noetic Fund has recently expanded its investment mandate with the launch of Fund II in February 2021, which broadens its focus beyond psychedelics to encompass a wider range of mental health solutions. The firm continues to actively support its portfolio companies, contributing to advancements in mental health treatments and technologies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.